| Document |
Document Title |
|
JP4814359B2 |
The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmac...
|
|
JP2011217750A |
To provide therapeutic proteins fused to albumin, or fragments or variants of the albumin.The present invention relates to: albumin fusion proteins comprising a therapeutic protein and the albumin including a specific sequence; nucleic a...
|
|
JP4805960B2 |
A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiati...
|
|
JP4799732B2 |
Methods are provided for forming hydrogel barriers in situ that adhere to tissue and prevent the formation of post-surgical adhesions or deliver drugs or other therapeutic agents to a body cavity. The hydrogels are crosslinked, resorb or...
|
|
JP4799804B2 |
A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiati...
|
|
JP4795362B2 |
The present invention provides (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-cyclopropyl-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-
yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate represented by the formula: which has superior pro...
|
|
JP4795620B2 |
The invention relates to compounds of formula (I) B-Q-X1, wherein B is a bioactive, cell adhesive mediating molecule, selected from the group (i) and Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 1) (ii), Trp-Tyr-Lys-Ile-Al...
|
|
JP4791921B2 |
An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (I): wherein R = NR6R7, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, hyterocyclic se...
|
|
JP4787919B2 |
A method and apparatus for lowering the body temperature of a patient while reducing shivering by using a heat exchange device in combination with an alpha2-adrenoreceptor agonist, a non-opiod analgesic monoamine uptake inhibitor or neur...
|
|
JP4781681B2 |
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be c...
|
|
JP4778531B2 |
The present invention provides compounds of formula (I). These compounds are a class of TAFIa inhibitors, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit ...
|
|
JP2011525116A |
The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, fo...
|
|
JP2011173900A |
To provide a medicine for a transplant patient to which an immunosuppressant is administered for a long time, wherein the medicine inhibits gradual fibrosing of an implanted organ to induce organ dysfunction, and to provide an immunologi...
|
|
JP4768440B2 |
The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions.
|
|
JP4769929B2 |
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
|
|
JP2011523878A |
Precut, user-shapeable, resorbable polymer micro-membranes are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions and to be absorbed into the body relatively slowly over tim...
|
|
JP4758063B2 |
Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.
|
|
JP4749331B2 |
The present invention provides a simple method for controlled differentiation of adipose-derived precursor cells. A method is provided for preparing a differentiated cell. The method comprises A) obtaining a mixture by mixing a) an adipo...
|
|
JP4752504B2 |
A blood storage container suitable for quick and efficient production of a large amount of serum while ensuring high safety, and a method of separating blood and a regenerative medical process using the same are provided. In a blood comp...
|
|
JP2011152133A |
To provide peptides, compositions, and methods for treating the proliferation of unwanted cells, such as benign and malignant tumors, glandular (e.g. prostate) hyperplasia, unwanted facial hair, warts, and unwanted fatty tissue.An NTP pe...
|
|
JP2011152428A |
To provide a high epithelial distension-retaining composition which can be easily injected as a solution through a thin catheter and allows retaining a high epithelial distension.The high epithelial distension-retaining composition compr...
|
|
JP4746244B2 |
Disclosed are viscoelastic compositions and methods of their use in surgical and non-surgical packing and in effecting drug delivery, especially in conjunction with trauma to of disorders of the ear.
|
|
JP4741183B2 |
This invention is related to the use of a composition formed by sodium hyaluronate, sodium chondroitin sulfate and botulinum toxin type A for the treatment of dermal lines, and to the use of such composition in the manufacture of a produ...
|
|
JP2011522020A |
Provided is the use of an agonist of a GABAA receptor for use in the prevention, reduction or inhibition of scarring formed on healing of a wound. Also provided is a method of preventing, reducing or inhibiting scarring formed on healing...
|
|
JP2011144189A |
To provide agonists or antagonists for a metabotropic glutamate receptor or an NAALADase enzyme.There are provided compounds represented by formula 1, for example, compounds of A and B.
|
|
JP4731801B2 |
Fluorinated alkanes (I) of formula F(CF2)n(CH2)mH (Ia) and F(CF2)n(CH2)m(CF2)nF (Ib) are new. n = 1-20; m = 3-20. Also claimed is a fluorinated n-alkane with density 1.1-1.3 g/cm<3>.
|
|
JP4733283B2 |
|
|
JP4731793B2 |
Methods are also provided for preparing stabilized formulations of whole antibody crystals or antibody fragment crystals using pharmaceutical ingredients or excipients and optionally encapsulating the crystals or crystal formulations in ...
|
|
JP2011520902A |
The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery.
|
|
JP2011121986A |
To provide methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing adhesion formation after surgical op...
|
|
JP4707294B2 |
The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at l...
|
|
JP4709393B2 |
The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelia...
|
|
JP4703607B2 |
This invention provides a compound of the following formula: or salts thereof, and a compound of the following formula: or salts thereof, wherein Y 1 , Y 2 , Y 3 and Y 4 are independently selected from N, CH, etc.; R 1 is H, C 1-8 alkyl,...
|
|
JP4703943B2 |
The invention provides an agent for conferring resistance comprising a lectin as an effective component, which are able to confer resistance against external stimuli to animal cells, particularly mammalian cells, and to their cultured ce...
|
|
JP4698837B2 |
The present invention provides rat connective tissue growth factor (CTGF), means for producing CTGF and therapeutic methods for using CTGF or derivatives therof.
|
|
JPWO2009101684A1 |
A drug for systemic administration for the prevention and / or treatment of visceral adhesions, which has the following general formula (I):[R1~ R5Indicates a hydrogen atom, an alkyl group, or an alkyl-substituted silyl group, X indicate...
|
|
JP2011105751A |
To provide an agent which modulates a signaling via PD-1.PD-1 is identified as a receptor of B7-4. B7-4 can inhibit the activation of an immunocyte when it is bonded to an inhibitory receptor on an immunocyte. Therefore, modulation of im...
|
|
JP2011105741A |
To provide a new method in use of a composition for treating chondropathy in osteoarthropathy.The method includes a drip-feed administration in the joint, of a viscoelastic solution comprising sodium hyaluronate and sodium chondroitin su...
|
|
JP2011105734A |
To provide a thiazole derivative which is a powerful cannabinoid (CB1) receptor antagonist, a powerful cannabinoid (CB1) receptor agonist or a powerful cannabinoid (CB1) receptor partial agonist and exhibits benefits for treating psychia...
|
|
JP2011517315T |
Infection according [the present invention] to infection, for example, bacteria, or infection by a protozoan, In order to occur with infection especially by gram-positivity and/or Gram-negative bacteria and gram-positivity, and/or Gram-n...
|
|
JP4690892B2 |
It is to provide a material to inhibit spine/spinal cord adhesion in the form of a sponge, a film or a suspension to be used for the purpose of assisting/accelerating the tissue healing. An adhesion inhibiting material for a spine/spinal...
|
|
JP2011102290A |
To provide a method for controlling one or more neurological deficits in patients having undergone cardiopulmonary bypass (CPB), because neurological deficits sometimes appear in patients having undergone CPB; the deficits relating to CP...
|
|
JP4685090B2 |
Disclosed is a substantially water-based medical hydrogel having at least 0.010 but no more than 50 crosslink points per molecule, as well as a dried material thereof. The hydrogel is obtained by crosslinking a gelatin having 20 to 30 am...
|
|
JP2011084566A |
To provide methods and compositions for inhibiting angiogenesis.There are provided methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to n...
|
|
JP4679730B2 |
|
|
JP4678895B2 |
Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery. In one embodiment, the compositions of this invention comprise a biocompatible polymer, a bi...
|
|
JP4676676B2 |
The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical ...
|
|
JP2011079851A |
To provide a composition for treating, preventing, and/or managing the myelofibrosis accompanied by myeloid metaplasia and with the refractory to the conventional treatment containing thalidomide.The composition includes 3-(4-amino-1-oxo...
|
|
JPWO2009066746A1 |
In the present invention, in a medium mainly composed of water, conditions that are mild to biological tissue components such as normal temperature and pressure without using physical methods such as chemical reaction, heat, light, and i...
|
|
JP2011510944A |
Tetrahydropyrimidines of the formula where R is a hydrogen atom or a hydrocarbon radical comprising up to eight carbon atoms, R′ is hydrogen, OH or OR″ and R″ is R or COR, with R having the above described significance for use in t...
|
